# An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections

> **NCT02302092** · PHASE3 · TERMINATED · sponsor: **Takeda** · enrollment: 13 (actual)

## Conditions studied

- Urinary Tract Infection

## Interventions

- **DRUG:** Flomoxef
- **DRUG:** Cefepime

## Key facts

- **NCT ID:** NCT02302092
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-01
- **Primary completion:** 2016-02-02
- **Final completion:** 2016-12-15
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Study was prematurely terminated due to administrative and strategic reasons
- **Last updated:** 2017-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02302092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02302092, "An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02302092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*